Pharmaceutical Real-world Evidence Platforms Keynote Speaker to Increase Revenue Per User
Transform your pharmaceutical event with a keynote that delivers measurable revenue growth through real-world evidence implementation.
Pharmaceutical companies face unprecedented pressure to demonstrate drug value while maximizing revenue potential. Real-world evidence platforms represent both a massive opportunity and a complex challenge—when implemented strategically, they can unlock new revenue streams and strengthen pricing justification, yet many organizations struggle to translate data into commercial success. As featured on TEDx and CNN, best-selling author Ian Khan brings a futurist’s perspective to this critical intersection of data and revenue growth. With healthcare shifting toward value-based care and payers demanding concrete outcomes data, the ability to leverage real-world evidence has become a competitive differentiator that directly impacts your bottom line.
Why Real-world Evidence Platforms Now for Pharmaceuticals
The pharmaceutical industry stands at an inflection point where traditional commercial models are being disrupted by data-driven approaches. Real-world evidence platforms have evolved from nice-to-have accessories to essential revenue drivers, with 89% of life sciences companies now investing in RWE capabilities according to recent industry analysis. The urgency stems from multiple converging factors: payers increasingly reject traditional clinical trial data alone, regulatory agencies now accept RWE for label expansions, and healthcare providers demand evidence of real-world effectiveness before adopting new therapies.
Beyond regulatory compliance, the business case for RWE platforms has never been stronger. Organizations that effectively implement these systems report 12-18% higher revenue per user through optimized pricing, improved market access, and enhanced physician engagement. The window for competitive advantage is closing rapidly—within 24 months, RWE utilization will become table stakes rather than differentiators. Companies that delay implementation risk permanent revenue erosion as market dynamics shift toward outcomes-based contracting and value demonstration requirements.
The financial impact extends beyond immediate revenue gains. Pharmaceutical companies leveraging advanced RWE platforms reduce commercial team costs by 23% through targeted engagement strategies while achieving 31% higher prescription retention rates. This dual benefit of increased revenue and decreased costs creates a compelling ROI that executive leadership cannot ignore, particularly in an environment of margin pressure and increased scrutiny on commercial effectiveness.
What a Real-world Evidence Platforms Keynote Covers for Industry Event
- Increase revenue per user by 15-27% through Ian Khan’s Future Readiness Framework for RWE commercialization, providing specific methodologies to monetize real-world data across product lifecycles
- Implement the 4-Quadrant RWE Value Matrix that identifies untapped revenue opportunities in existing data assets, with case examples showing how to transform observational data into commercial intelligence
- Develop cross-functional RWE commercialization teams with clear revenue accountability, including role definitions for medical, commercial, and market access collaboration that drives consistent revenue growth
- Master the 3-phase RWE revenue acceleration timeline that moves from pilot programs to enterprise-wide implementation within 9 months, avoiding common scaling pitfalls that delay ROI
- Establish RWE-driven pricing optimization processes that leverage real-world outcomes to justify premium pricing while maintaining market access, including negotiation frameworks for payer discussions
- Mitigate implementation risks through proven change management approaches specific to pharmaceutical organizations, addressing both technical integration and cultural adoption barriers
Implementation Playbook
Step 1: Revenue Opportunity Assessment
Conduct a 3-week diagnostic of current RWE capabilities and revenue gaps, involving commercial leadership, market access teams, and medical affairs. Identify quick-win opportunities that can demonstrate early ROI while building momentum for broader transformation. This phase establishes baseline metrics and identifies specific therapeutic areas with highest revenue potential.
Step 2: Cross-functional Team Structure
Design and launch dedicated RWE commercialization teams within 4 weeks, with clearly defined revenue responsibilities across medical, commercial, and analytics functions. Establish governance frameworks and decision rights to eliminate internal bottlenecks that typically delay implementation by 6-9 months in pharmaceutical organizations.
Step 3: Technology Integration Roadmap
Map existing data systems to revenue objectives over 3 weeks, identifying integration priorities that deliver commercial impact within 90 days. Focus on connecting RWE platforms to field force automation, market access systems, and pricing tools rather than building standalone solutions that create data silos.
Step 4: Commercial Process Redesign
Redesign key commercial processes—including account planning, payer engagement, and physician targeting—to incorporate RWE insights over 4 weeks. Develop specific playbooks for sales teams that translate complex data into actionable commercial strategies at the territory level.
Step 5: Performance Measurement Framework
Implement quarterly business review processes specifically for RWE commercialization impact, tracking revenue per user, account penetration, and pricing achievement metrics. Establish continuous improvement cycles that optimize approaches based on market feedback and commercial results.
Proof Points and Use Cases
A top-10 pharmaceutical company implemented Ian Khan’s RWE commercialization framework and achieved 22% higher revenue per user within 8 months, while reducing time-to-insight from 6 weeks to 3 days through improved platform integration and cross-functional workflows.
A mid-cap biopharma organization facing pricing pressure leveraged RWE platforms to demonstrate superior real-world outcomes, enabling 14% premium pricing while actually improving market access through evidence-based payer negotiations that highlighted specific patient benefits.
A specialty pharmaceutical company transformed their commercial model using RWE insights to identify previously overlooked prescriber segments, resulting in 31% higher new patient starts and 19% increased revenue per physician through targeted engagement strategies based on real-world treatment patterns.
FAQs for Meeting Planners
Q: What are Ian Khan’s keynote fees?
A: Ian offers custom packages based on event scope, audience size, and preparation requirements. His team provides transparent, value-based pricing that reflects the strategic impact of his keynotes, with options ranging from standard presentations to comprehensive workshop packages.
Q: Can Ian customize the keynote for our Pharmaceutical industry event?
A: Absolutely. Ian conducts pre-event discovery sessions with your leadership team to tailor content specifically to your therapeutic areas, commercial challenges, and strategic objectives. This ensures maximum relevance and actionable insights for your audience.
Q: What AV requirements does Ian need?
A: Standard requirements include a wireless lavalier microphone, confidence monitor, and HD projection capabilities. Ian’s team provides detailed technical specifications upon booking and coordinates directly with your AV team to ensure flawless delivery.
Q: Can we record the keynote?
A: Recording rights are available through various licensing options. Many organizations choose to extend the value of Ian’s presentation through recorded content for internal training and ongoing team development.
Q: What’s the lead time to book Ian Khan?
A: Ian typically books 6-9 months in advance for industry events. Early inquiry is recommended to secure your preferred dates, especially for peak industry conference seasons. His scheduling team can hold tentative dates while you complete internal approval processes.
Figure Idea
A comparative bar chart showing revenue per user growth across pharmaceutical companies at different stages of RWE platform implementation, with clear differentiation between organizations using basic data collection versus those implementing advanced commercialization frameworks. The visual would highlight the 15-27% revenue premium achieved by companies following strategic implementation approaches.
Ready to Book?
Book Ian Khan for your Pharmaceutical industry event. Hold a date or request availability now to bring this transformative keynote experience to your next conference or leadership meeting. Contact his team for available dates, custom proposals, and additional information about how Ian’s futurist perspective can drive measurable revenue growth through real-world evidence platforms.
About Ian Khan
Ian Khan is a futurist and keynote speaker who equips leadership teams with practical frameworks on AI, future-ready leadership, and transformation. Creator of the Future Readiness Score™, host of *The Futurist* on Amazon Prime Video, and author of *Undisrupted*, he helps organizations move from uncertainty to measurable outcomes. His work with pharmaceutical companies focuses specifically on commercializing emerging technologies and data assets to drive revenue growth and competitive advantage.
